Physician profile
Parul Sinha
NPI 1104118066
$2,228.51
in general payments reported to CMS, 2019-2025
23 companies · $193 in 2025
The $193 reported for 2025 was less than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $145 · 2020: $14.13 · 2021: $227 · 2022: $880 · 2023: $391 · 2024: $379 · 2025: $193.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $963.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $962.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $961.55 | 2021-2022 | |
| Optinose US, INC. | $231.19 | 2022-2025 | |
| Aerin Medical INC. | $150.86 | 2024 | |
| Zimmer Biomet Holdings, INC. | $108.56 | 2021 | |
| Medtronic, INC. | $106.20 | 2023-2025 | Sinuva |
| Tactile Systems Technology INC | $105.63 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $67.75 | 2023-2024 | Dupixent |
| Genzyme Corporation | $67.29 | 2023 | |
| Inspire Medical Systems, INC. | $60.94 | 2023-2025 | Inspire |
| Novartis Pharmaceuticals Corporation | $56.47 | 2023 | |
| Integra Lifesciences Corporation | $47.55 | 2024-2025 | Trudi Probe, Inspira Air, Acclarent Aera |
| Glaxosmithkline, LLC. | $45.52 | 2022-2023 | Nucala |
| Acclarent, INC | $29.11 | 2023 | Acclarent Aera |
| Blueprint Medicines Corporation | $25.27 | 2024 | Ayvakit |
| Takeda Pharmaceuticals U.S.A., INC. | $23.48 | 2025 | Takhzyro |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $22.86 | 2024 | Olympus |
| Med-El Corporation | $19.56 | 2019 | |
| Intersect Ent, INC. | $19.53 | 2019 | |
| Amgen INC. | $18.30 | 2023 | Tezspire |
| Hikma Pharmaceuticals USA | $17.79 | 2024 | Ryaltris |
| Kaleo, INC. | $15.46 | 2023 | Auvi-Q |
| Medtronic USA, INC. | $14.13 | 2020 | |
| Neurent Medical Limited | $13.51 | 2024 | Neuromark Radiofrequency Console, Neuromark Device |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Parul Sinha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.